CHLOE PERATE: Open Payments
NPI 1336705664 · BRYN MAWR, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,587 in 117 payments from 31 companies in 2025. Trend: 2023 $651 · 2024 $2,895 · 2025 $2,587
Food & beverage: $2,587
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $438 |
| Novartis Pharmaceuticals Corporation | 12 | $285 |
| Astellas Pharma US Inc | 10 | $188 |
| Genentech USA, Inc. | 9 | $174 |
| Incyte Corporation | 8 | $161 |
| Janssen Biotech, Inc. | 7 | $147 |
| Eisai Inc. | 5 | $128 |
| Merck Sharp & Dohme LLC | 4 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $84 |
| GlaxoSmithKline, LLC. | 3 | $80 |
Products named: Enhertu, TAGRISSO, Lenvima, JAKAFI, KISQALI, KEYTRUDA, Fabhalta, VENCLEXTA.
Industry payments across PA — which companies pay providers there.
